Organotropic targeting of biomimetic nanoparticles to treat lung disease

Summary

This research addresses organ-level drug targeting without first identifying a unique receptor and constructing a synthetic ligand for it. The authors exploited the natural lung tropism of exosomes from metastatic breast cancer cells, whose surface marker profile favors localization to lung tissue. Those exosomal membranes were used to coat nanoparticle cores containing dexamethasone, creating a biomimetic carrier for an anti-inflammatory payload. In vivo testing showed that the coated particles accumulated in the lungs more strongly than the relevant comparison formulation and substantially lowered the burden of proinflammatory cytokines in a model of lung inflammation. The principal finding is therefore that a naturally organotropic biological surface can transfer its homing behavior to a drug nanocarrier while supporting a measurable therapeutic response. This approach differs from conventional active targeting because it uses a pre-existing cellular trafficking program rather than a separately selected receptor–ligand pair. The study's significance lies in demonstrating a route to organ-specific delivery that may simplify targeting design for certain diseases. The abstract supports efficacy in an inflammatory model but does not establish how broadly the strategy applies or address the risks of using cancer-cell-derived exosomal material.